IBB News and Press, iShares Biotechnology ETF From 06/09/22

iShares Nasdaq Biotechnology ETF (IBB) - $0.0305. 30-Day SEC Yield of 0.24% as of April. 29. Payable Jun 15; for shareholders of record Jun 10; ex-div Jun 09. For further details see: iShares Nasdaq Biotechnology ETF declares quarterly distribution of $0.0305

One of the best parts about penny stocks is that there are so many of them right now. Similar to what we saw during the pandemic, hundreds of companies had fallen victim to the broad sector sell-offs this year. It hasn’t only been “start-ups” either. Plenty of househo...

Biotechnology sector stocks seem to be in the oversold zone, as indicated by their momentum and valuations. I compared XBI (small-cap biotech ETF) and IBB (all-cap biotech ETF) to select the most promising one. IBB seems to be much more expensive than XBI based on the price-to-ear...

From the March ’22 lows, the SP 500 traded up to 4,637 on March 29th, accounting for an approximate 11.5% rally. Right now, the only way the Fed can seem to deviate from its current course is if jobless claims start to rise (jobless claims actually bottomed in late March ȁ...

Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023. PLN-74809 is also being explored for the treatment of patients with idiopathic pulmonary fibrosis; Preliminary safety and effic...

Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release. Blarcamesine likely scavenges peroxynitrite.  I...

As the recent Rett syndrome controversy shows, Anavex is a perpetually beleaguered stock. Despite the tremendous bearish headwind it always faces, the company has been able to increase shareholder value over the years. However, AVXL is still a highly risky, high blood pressure sto...

Biotechs have sold off this year along with the broader market. Declines have been more pronounced than prior pullbacks. However, healthcare continues to outperform. Federal Reserve's interest rate policy will continue to place a heavy burden on biotechs through much of the third quar...

An Emergency Use Authorization submission of sabizabulin for high-risk hospitalized Covid-19 patients is expected Q2 of 2022. With EUA and then possibly NDA occurring for sabizabulin, Veru would be in a good position to develop advance purchase orders with several Government agencies ...

Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or meta...